{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:05:26Z","timestamp":1789175126223,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010559","name":"Pitt | University of Pittsburgh Medical Center | Children\u2019s Hospital of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010559","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","award":["CAMS 1013362.01"],"award-info":[{"award-number":["CAMS 1013362.01"]}],"id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005886","name":"Pediatric Infectious Diseases Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005886","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pitt | University of Pittsburgh Medical Center | Children\u2019s Hospital of Pittsburgh"},{"name":"Pitt | University of Pittsburgh Medical Center | Children\u2019s Hospital of Pittsburgh"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rift Valley fever virus (RVFV) is a hemorrhagic fever virus with the potential for significant economic and public health impact. Vaccination with an attenuated strain, DelNSsRVFV, provides protection from an otherwise lethal RVFV challenge, but mechanistic determinants of protection are undefined. In this study, a murine model was used to assess the contributions of humoral and cellular immunity to DelNSsRVFV-mediated protection. Vaccinated mice depleted of T cells were protected against subsequent challenge, and passive transfer of immune serum from vaccinated animals to na\u00efve animals was also protective, demonstrating that T cells were dispensable in the presence of humoral immunity and that humoral immunity alone was sufficient. Animals depleted of B cells and then vaccinated were protected against challenge. Total splenocytes, but not T cells alone, B cells alone, or B\u2009+\u2009T cells harvested from vaccinated animals and then transferred to na\u00efve animals were sufficient to confer protection, suggesting that multiple cellular interactions were required for effective cellular immunity. Together, these data indicate that humoral immunity is sufficient to confer vaccine-mediated protection and suggests that cellular immunity plays a role in protection that requires the interaction of various cellular components.<\/jats:p>","DOI":"10.1038\/s41541-022-00551-4","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T19:08:25Z","timestamp":1666984105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Immune correlates of protection following Rift Valley fever virus vaccination"],"prefix":"10.1038","volume":"7","author":[{"given":"Joshua D.","family":"Doyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6493-5022","authenticated-orcid":false,"given":"Dominique J.","family":"Barbeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley N.","family":"Cartwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6764-7536","authenticated-orcid":false,"given":"Anita K.","family":"McElroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"551_CR1","first-page":"797","volume":"25","author":"B Mundel","year":"1951","unstructured":"Mundel, B. & Gear, J. Rift valley fever; I. The occurrence of human cases in Johannesburg. S Afr. Med. J. 25, 797\u2013800 (1951).","journal-title":"S Afr. Med. J."},{"key":"551_CR2","first-page":"514","volume":"29","author":"J Gear","year":"1955","unstructured":"Gear, J. et al. Rift valley fever in South Africa; a study of the 1953 outbreak in the Orange Free State, with special reference to the vectors and possible reservoir hosts. S Afr. Med. J. 29, 514\u2013518 (1955).","journal-title":"S Afr. Med. J."},{"key":"551_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/0035-9203(79)90005-1","volume":"73","author":"H Hoogstraal","year":"1979","unstructured":"Hoogstraal, H., Meegan, J. M., Khalil, G. M. & Adham, F. K. The Rift Valley fever epizootic in Egypt 1977-78. 2. Ecological and entomological studies. Trans. R. Soc. Trop. Med. Hyg. 73, 624\u2013629 (1979).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"551_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/0035-9203(79)90004-X","volume":"73","author":"JM Meegan","year":"1979","unstructured":"Meegan, J. M. The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizzotic and virological studies. Trans. R. Soc. Trop. Med. Hyg. 73, 618\u2013623 (1979).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"551_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2460\/javma.234.7.883","volume":"234","author":"BH Bird","year":"2009","unstructured":"Bird, B. H., Ksiazek, T. G., Nichol, S. T. & Maclachlan, N. J. Rift Valley fever virus. J. Am. Vet. Med. Assoc. 234, 883\u2013893 (2009).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"551_CR6","first-page":"1","volume":"30","author":"KC Smithburn","year":"1949","unstructured":"Smithburn, K. C. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br. J. Exp. Pathol. 30, 1\u201316 (1949).","journal-title":"Br. J. Exp. Pathol."},{"key":"551_CR7","first-page":"261","volume":"61","author":"F Assaad","year":"1983","unstructured":"Assaad, F. et al. The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from a WHO\/FAO meeting. Bull. World Health Organ. 61, 261\u2013268 (1983).","journal-title":"Bull. World Health Organ"},{"key":"551_CR8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4049\/jimmunol.93.2.293","volume":"93","author":"R Randall","year":"1964","unstructured":"Randall, R., Binn, L. N. & Harrison, V. R. Immunization against rift valley fever virus. studies on the immunogenicity of lyophilized formalin-inactivated vaccine. J. Immunol. 93, 293\u2013299 (1964).","journal-title":"J. Immunol."},{"key":"551_CR9","first-page":"160","volume":"77","author":"LN Binn","year":"1963","unstructured":"Binn, L. N., Randall, R., Harrison, V. R., Gibbs, C. J. & Aulisio, C. G. Immunization against Rift Valley fever. The development of vaccines from nonprimate cell cultures and chick embryos. Am. J. Hyg. 77, 160\u2013168 (1963).","journal-title":"Am. J. Hyg."},{"key":"551_CR10","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4049\/jimmunol.89.5.660","volume":"89","author":"R Randall","year":"1962","unstructured":"Randall, R., Gibbs, C. J., Aulisio, C. G., Binn, L. N. & Harrison, V. R. The development of a formalin-killed Rift Valley fever virus vaccine for use in man. J. Immunol. 89, 660\u2013671 (1962).","journal-title":"J. Immunol."},{"key":"551_CR11","first-page":"45","volume":"48","author":"BJ Barnard","year":"1977","unstructured":"Barnard, B. J. & Botha, M. J. An inactivated rift valley fever vaccine. J. S Afr. Vet. Assoc. 48, 45\u201348 (1977).","journal-title":"J. S Afr. Vet. Assoc."},{"key":"551_CR12","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1128\/JVI.02501-07","volume":"82","author":"BH Bird","year":"2008","unstructured":"Bird, B. H. et al. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J. Virol. 82, 2681\u20132691 (2008).","journal-title":"J. Virol."},{"key":"551_CR13","doi-asserted-by":"publisher","first-page":"e0006474","DOI":"10.1371\/journal.pntd.0006474","volume":"12","author":"DR Smith","year":"2018","unstructured":"Smith, D. R. et al. Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. PLoS Negl. Trop. Dis. 12, e0006474 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"551_CR14","doi-asserted-by":"publisher","first-page":"12901","DOI":"10.1128\/JVI.06046-11","volume":"85","author":"BH Bird","year":"2011","unstructured":"Bird, B. H. et al. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J. Virol. 85, 12901\u201312909 (2011).","journal-title":"J. Virol."},{"key":"551_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/srep20617","volume":"6","author":"GM Warimwe","year":"2016","unstructured":"Warimwe, G. M. et al. Chimpanzee adenovirus vaccine provides multispecies protection against rift valley fever. Sci. Rep. 6, 20617 (2016).","journal-title":"Sci. Rep."},{"key":"551_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00476-y","volume":"7","author":"PJ Wichgers Schreur","year":"2022","unstructured":"Wichgers Schreur, P. J. et al. Safety and immunogenicity of four-segmented Rift Valley fever virus in the common marmoset. npj Vaccines 7, 54 (2022).","journal-title":"npj Vaccines"},{"key":"551_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fvets.2020.00256","volume":"7","author":"DB Wallace","year":"2020","unstructured":"Wallace, D. B. et al. Protection of cattle elicited using a bivalent lumpy skin disease virus-vectored recombinant rift valley fever vaccine. Front. Vet. Sci. 7, 256 (2020).","journal-title":"Front. Vet. Sci."},{"key":"551_CR18","first-page":"197","volume":"92","author":"BS Niklasson","year":"1984","unstructured":"Niklasson, B. S., Meadors, G. F. & Peters, C. J. Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters. Acta. Pathol. Microbiol. Immunol. Scand. C. 92, 197\u2013200 (1984).","journal-title":"Acta. Pathol. Microbiol. Immunol. Scand. C."},{"key":"551_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF01311021","volume":"99","author":"CJ Peters","year":"1988","unstructured":"Peters, C. J. et al. Experimental Rift Valley fever in rhesus macaques. Arch. Virol. 99, 31\u201344 (1988).","journal-title":"Arch. Virol."},{"key":"551_CR20","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.1128\/JVI.00337-13","volume":"87","author":"KA Dodd","year":"2013","unstructured":"Dodd, K. A., McElroy, A. K., Jones, M. E. B., Nichol, S. T. & Spiropoulou, C. F. Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses. J. Virol. 87, 6161\u20136171 (2013).","journal-title":"J. Virol."},{"key":"551_CR21","doi-asserted-by":"crossref","unstructured":"Harmon, J. R. et al. CD4 T cells, CD8 T cells, and monocytes coordinate to prevent rift valley fever virus encephalitis. J. Virol. 92, e01270\u201318 (2018).","DOI":"10.1128\/JVI.01270-18"},{"key":"551_CR22","doi-asserted-by":"publisher","first-page":"e0150621","DOI":"10.1128\/JVI.01506-21","volume":"95","author":"DJ Barbeau","year":"2021","unstructured":"Barbeau, D. J. et al. Identification and characterization of rift valley fever virus-specific T cells reveals a dependence on CD40\/CD40L interactions for prevention of encephalitis. J. Virol. 95, e0150621 (2021).","journal-title":"J. Virol."},{"key":"551_CR23","first-page":"161","volume":"44","author":"A Pini","year":"1973","unstructured":"Pini, A., Lund, L. J. & Davies, F. G. Fluorescent and neutralizing antibody response to infection by Rift Valley fever virus. J. S Afr. Vet. Assoc. 44, 161\u2013165 (1973).","journal-title":"J. S Afr. Vet. Assoc."},{"key":"551_CR24","first-page":"155","volume":"50","author":"BJ Barnard","year":"1979","unstructured":"Barnard, B. J. Rift Valley fever vaccine\u2013antibody and immune response in cattle to a live and an inactivated vaccine. J. S Afr. Vet. Assoc. 50, 155\u2013157 (1979).","journal-title":"J. S Afr. Vet. Assoc."},{"key":"551_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0166-9","volume":"5","author":"JR Harmon","year":"2020","unstructured":"Harmon, J. R., Barbeau, D. J., Nichol, S. T., Spiropoulou, C. F. & McElroy, A. K. Rift Valley fever virus vaccination induces long-lived, antigen-specific human T cell responses. npj Vaccines 5, 17 (2020).","journal-title":"npj Vaccines"},{"key":"551_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0264-410X(85)90061-1","volume":"3","author":"B Niklasson","year":"1985","unstructured":"Niklasson, B., Peters, C. J., Bengtsson, E. & Norrby, E. Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans. Vaccine 3, 123\u2013127 (1985).","journal-title":"Vaccine"},{"key":"551_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","volume":"9","author":"JC Morrill","year":"1991","unstructured":"Morrill, J. C. et al. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 9, 35\u201341 (1991).","journal-title":"Vaccine"},{"key":"551_CR28","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1016\/j.vaccine.2010.02.018","volume":"28","author":"G Lorenzo","year":"2010","unstructured":"Lorenzo, G., Mart\u00edn-Folgar, R., Hevia, E., Boshra, H. & Brun, A. Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-\/-) mice induced by different DNA vaccination regimens. Vaccine 28, 2937\u20132944 (2010).","journal-title":"Vaccine"},{"key":"551_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0166-3542(85)90044-0","volume":"5","author":"KW McIntyre","year":"1985","unstructured":"McIntyre, K. W., Bukowski, J. F. & Welsh, R. M. Exquisite specificity of adoptive immunization in arenavirus-infected mice. Antivir. Res. 5, 299\u2013305 (1985).","journal-title":"Antivir. Res."},{"key":"551_CR30","doi-asserted-by":"publisher","first-page":"6874","DOI":"10.1073\/pnas.94.13.6874","volume":"94","author":"O Planz","year":"1997","unstructured":"Planz, O. et al. A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. Proc. Natl Acad. Sci. USA 94, 6874\u20136879 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"551_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1006\/viro.1999.0074","volume":"266","author":"DP Berger","year":"2000","unstructured":"Berger, D. P., Homann, D. & Oldstone, M. B. Defining parameters for successful immunocytotherapy of persistent viral infection. Virology 266, 257\u2013263 (2000).","journal-title":"Virology"},{"key":"551_CR32","doi-asserted-by":"publisher","first-page":"21182","DOI":"10.1073\/pnas.1118450109","volume":"108","author":"RD Aubert","year":"2011","unstructured":"Aubert, R. D. et al. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc. Natl Acad. Sci. USA 108, 21182\u201321187 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"551_CR33","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.4049\/jimmunol.175.2.1184","volume":"175","author":"KL Warfield","year":"2005","unstructured":"Warfield, K. L. et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J. Immunol. 175, 1184\u20131191 (2005).","journal-title":"J. Immunol."},{"key":"551_CR34","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.4049\/jimmunol.180.6.4058","volume":"180","author":"SB Bradfute","year":"2008","unstructured":"Bradfute, S. B., Warfield, K. L. & Bavari, S. Functional CD8+ T cell responses in lethal Ebola virus infection. J. Immunol. 180, 4058\u20134066 (2008).","journal-title":"J. Immunol."},{"key":"551_CR35","doi-asserted-by":"publisher","first-page":"13934","DOI":"10.1128\/JVI.79.22.13934-13942.2005","volume":"79","author":"IS Lukashevich","year":"2005","unstructured":"Lukashevich, I. S. et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J. Virol. 79, 13934\u201313942 (2005).","journal-title":"J. Virol."},{"key":"551_CR36","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.vaccine.2011.12.134","volume":"30","author":"MA Goicochea","year":"2012","unstructured":"Goicochea, M. A. et al. Evaluation of Lassa virus vaccine immunogenicity in a CBA\/J-ML29 mouse model. Vaccine 30, 1445\u20131452 (2012).","journal-title":"Vaccine"},{"key":"551_CR37","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.3389\/fmicb.2020.01962","volume":"11","author":"HN Cartwright","year":"2020","unstructured":"Cartwright, H. N., Barbeau, D. J. & McElroy, A. K. Rift valley fever virus is lethal in different inbred mouse strains independent of sex. Front. Microbiol. 11, 1962 (2020).","journal-title":"Front. Microbiol."},{"key":"551_CR38","doi-asserted-by":"publisher","first-page":"e2874","DOI":"10.1371\/journal.pntd.0002874","volume":"8","author":"KA Dodd","year":"2014","unstructured":"Dodd, K. A. et al. Rift valley Fever virus encephalitis is associated with an ineffective systemic immune response and activated T cell infiltration into the CNS in an immunocompetent mouse model. PLoS Negl. Trop. Dis. 8, e2874 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"551_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.virol.2007.01.046","volume":"362","author":"BH Bird","year":"2007","unstructured":"Bird, B. H., Albari\u00f1o, C. G. & Nichol, S. T. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 362, 10\u201315 (2007).","journal-title":"Virology"},{"key":"551_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1743-422X-6-125","volume":"6","author":"AK McElroy","year":"2009","unstructured":"McElroy, A. K., Albari\u00f1o, C. G. & Nichol, S. T. Development of a RVFV ELISA that can distinguish infected from vaccinated animals. Virol. J. 6, 125 (2009).","journal-title":"Virol. J."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00551-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00551-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00551-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T13:29:58Z","timestamp":1678454998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00551-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00551-4","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"28 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}